The FDA Could Ease Restrictions On Peptides This Summer—What Consumers Should Know

A U.S. Food and Drug Administration (FDA) advisory committee is meeting in July to consider loosening restrictions around ...
JD Supra

FDA Signals Potentially Evolving Stance Toward Compounding of Certain Peptides

On April 15, 2026, the U.S. Food and Drug Administration (“FDA”) announced that it will convene a public meeting of the Pharmacy Compounding ...
JD Supra

The Shot Heard ‘Round the Pharmacy’: FDA Takes Aim at GLP-1 Compounders

On May 1, the US Food and Drug Administration (FDA) announced that it is proposing to exclude semaglutide, tirzepatide, and liraglutide from the ...
Medical News Today

FDA proposes ban on bulk compounding of semaglutide and tirzepatide

The FDA has proposed excluding weight-loss drugs, such as Ozempic/Wegovy and Zepbound from a key compounding list, ...
RAPS

FDA Issues Drug Compounding Small Entity Compliance Guide

In April, FDA detailed its priorities for drug compounding in 2019, which include issuing a new proposed rule to update the list of bulk drug substances that can be used in compounding under Section ...
RAPS

Drug Compounding With Bulk Substances: FDA Offers Interim Policies

The US Food and Drug Administration (FDA) late Friday issued revised versions of two final guidance documents explaining the use of bulk drug substances in compounding and clarifying that the agency ...